Market news

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

Surgery Partners’s 30.8% return over the past six months has outpaced the S&P 500 by 12.8%, and its stock price has climbed to $15.67 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Surgery Partners (SGRY) said Thursday it expects full-year 2026 revenue of $3.08 billion to $3.18 bi

As the stock price dips lower, this executive purchase shows confidence in the future of Surgery Partners.

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Surgery Partners’ second quarter results were received positively by the market, with management highlighting that revenue and adjusted EBITDA came in ahead of expectations. CEO Eric Evans credited growth in higher-acuity surgical procedures—particularly in orthopedics, vascular, and spine—as a primary driver, despite overall surgical case volumes remaining flat. Management also pointed to the company’s ongoing focus on recruiting new physicians and maintaining strong relationships with clinical

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the outpatient & specialty care stocks, including Surgery Partners (NASDAQ:SGRY) and its peers.

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Healthcare company Surgery Partners (NASDAQ:SGRY) will be announcing earnings results this Monday before market hours. Here’s what to expect.

Surgery Partners (SGRY) has an average rating of overweight and mean price target of $18.73, accordi

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Motley Fool Press Release.

Surgery Partners (SGRY) reported Q2 adjusted net income Monday of $0.10 per adjusted diluted share,

Healthcare company Surgery Partners (NASDAQ:SGRY) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.7% year on year to $848.9 million. The company expects the full year’s revenue to be around $3.4 billion, close to analysts’ estimates. Its non-GAAP profit of $0.10 per share was 49.4% above analysts’ consensus estimates.

Surgery Partners: Q2 Earnings Snapshot

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Surgery Partners (SGRY) Q2 Earnings: What To Expect

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

/DISREGARD RELEASE: Premier Plastic Surgery Partners/

The regional nonprofit and the surgical facility operator have co-owned the facilities since 2023. But Surgery Partners, which expects to net almost $800 million from the deal, is looking to reorient its portfolio towards outpatient care.

Surgery Partners rises after agreeing to sell Idaho Falls hospital stakes for $795 million while reaffirming its 2026 outlook

Surgery Partners (SGRY) has entered into definitive agreements to sell its ownership interests in Mo

Patients are no longer waiting until facial aging becomes severe before considering cosmetic surgery. According to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the average age of facelift patients continues to decline as more individuals pursue preventive structural rejuvenation designed to maintain youthful facial contours rather than reverse decades of aging.

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Surgery Partners (SGRY) has drawn investor attention after recent share price moves, with the stock up over the past month and past 3 months while longer term returns remain under pressure. See our latest analysis for Surgery Partners. Over the past year, Surgery Partners has seen a 1-year total shareholder return decline of 25.59%. Recent momentum has picked up, with a 30-day share price return of 15.49% and a 90-day share price return of 27.03% from a latest share price of US$16.40. If you...

Surgery Partners (SGRY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.